https://www.selleckchem.com/products/en460.html
As MUTYH is intimately associated with targetable molecular partners, therapeutic options for MUTYH driven ovarian cancers include programed-death 1/programed-death ligand-1 inhibitors and poly-adenosine diphosphate ribose polymerase inhibitors. Understanding the function of MUTYH and its associated partners is critical for determining screening, risk reduction, and therapeutic approaches for MUTYH-driven ovarian cancers.Glioblastoma (GBM) is the most common malignant brain tumor and its malignant phenotypic characteristics are classified
Giống
Bình luận
Đăng lại
